ClinicalTrials.gg
RecruitingNCT07080697Updated Jul 23, 2025

A Study to Evaluate Splenectomy on Debridement for Acute Necrotizing Pancreatitis With Pancreatic Sinistral Portal Hypertension

An interventional study of Splenectomy and Control in Acute Necrotizing Pancreatitis and Portal Hypertension, sponsored by Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by Zhejiang University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Pancreatitis, Acute Necrotizing with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Pancreatitis, Acute Necrotizing · China.

Planned enrollment
10th of 14
66 · median 135
Started
2025
with 2 others
No phase
8 of 17
4 open now
Registered
15th of 17
by date

Among the 17 studies in Pancreatitis, Acute Necrotizing with a site in China, this one is the 10th largest by planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2025, is one of 8 with no phase, and was the 15th registered.

Pancreatitis, Acute Necrotizing

75 studies on the registry are indexed under Pancreatitis, Acute Necrotizing; 20 are open to participants now.

Browse Pancreatitis, Acute Necrotizing studies →

Open to participants now

6 of the 17 studies in Pancreatitis, Acute Necrotizing with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 12 Pancreatitis, Acute Necrotizing studies recruiting now, 9 (75%) set no upper age limit and 3 (25%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pancreatitis, Acute Necrotizing with a site in China, or all of them as a file.
02

Study summary

This study is a prospective, single-center, randomized controlled trial focusing on patients with acute necrotizing pancreatitis (ANP) complicated by pancreatic sinistral portal hypertension (PSPH). The study aims to study the impact of total splenectomy on the debridement efficacy, perioperative recovery, and prognosis of patients with ANP complicated by PSPH.

Read the detailed description

This study is a prospective, single-center, randomized controlled trial focusing on patients with acute necrotizing pancreatitis (ANP) complicated by pancreatic sinistral portal hypertension (PSPH). A total of 66 participants are planned to be enrolled. The study aims to compare the outcomes of two surgical approaches: open debridement combined with distal pancreatectomy and total splenectomy versus open debridementalone. The objective is to observe the impact of total splenectomy on the debridement efficacy, perioperative recovery, and prognosis of patients with ANP complicated by PSPH. The primary observational indicators include postoperative length of hospital stay, postoperative cost, postoperative life quality, and the alleviation of PSPH. Secondary observational indicators encompass the number of unplanned reoperations, postoperative infection control, postoperative irrigation volume, postoperative antibiotic consumption, and postoperative platelet count change. The study will be carried out in accordance with the protocol.

03

Conditions studied

  • Acute Necrotizing Pancreatitis
  • Portal Hypertension

Keywords

  • Acute Necrotizing Pancreatitis
  • Pancreatic Sinistral Portal Hypertension
  • Debridement
  • Splenectomy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 75 years.
  2. Acute necrotic pancreatitis complicated by pancreatic sinistral portal hypertension.
  3. Patients undergoing open debridement for infected pancreatic necrosis

Exclusion criteria

Exclusion Criteria:

  1. Patients with pre-existing heart, lung, liver, kidney, or other organ failure prior to acute pancreatitis (AP).
  2. Patients with pre-existing conditions such as cirrhosis that may lead to portal hypertension prior to AP.
  3. Patients with pre-existing hematological diseases prior to AP.
  4. Patients undergoing laparoscopic or nephroscopic debridement.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Splenectomy group

    Open Debridement combined with Distal Pancreatectomy and Total Splenectomy

    Procedure: Splenectomy

  • Experimental
    Control group

    Open Debridement alone

    Procedure: Control

Interventions

  • ProcedureSplenectomy

    Open Debridement combined with distal pancreatectomy and total splenectomy

  • ProcedureControl

    Open Debridement alone

06

What researchers measure

Primary outcomes

  1. Length of hospital stay after debridement

    The total length of hospital stay after debridement, including readmissions.

    Time frame: From enrollment of the first subject to completion of follow-up of the last subject (up to 5 years)

  2. Degree of pancreatic sinistral portal hypertension

    The degree of pancreatic sinistral portal hypertension after intervention

    Time frame: From enrollment of the first subject to completion of follow-up of the last subject (up to 5 years)

Secondary outcomes

  1. Intensive Care Unit stay post Operation

    Time frame: Perioperative

  2. Pancreatic Fistula

    The rate of pancreatic fistula

    Time frame: Perioperative

  3. Number of Draining Tube when Discharged

    Time frame: Perioperative

  4. Time of all draining tubes removal

    Time frame: From enrollment of the first subject to completion of follow-up of the last subject (up to 5 years)

  5. Cost post debridement in the first hospitalization

    Time frame: Perioperative

  6. Number of unplanned re-admissions

    Time frame: From enrollment of the first subject to completion of follow-up of the last subject (up to 5 years)

  7. Number of unplanned operations

    Time frame: From enrollment of the first subject to completion of follow-up of the last subject (up to 5 years)

  8. Number of percutaneous drainage after debridement

    Time frame: From enrollment of the first subject to completion of follow-up of the last subject (up to 5 years)

  9. Antibiotic use after treatment

    Time frame: Perioperative

  10. Abdominal lavage

    Abdominal lavage volume after treatment

    Time frame: Perioperative

  11. Life quality one year after treatment

    Life quality one year after treatment was judged by the Short-Form 36 Health Survey (SF-36), encompassing both physical and mental health across eight dimensions: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The minimum value is 0%, the maximum value is 100%, and a higher score means a better life quality.

    Time frame: Within one year after the last subject was treated

Other outcomes

  1. Platelet number after debridement

    Time frame: Within one year after the last subject was treated

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Feb 2027, 18 months later.

Of 20 interventional studies with no phase under Pancreatitis, Acute Necrotizing, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 36. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2025
First posted
Jul 23, 2025
StartEst.
Jul 30, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 29, 2028
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07080697
Responsible party
TingBo Liang (Director physician, Zhejiang University) — Principal investigator
First posted
Jul 23, 2025
Start date
Jul 30, 2025 (estimated)
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 29, 2028 (estimated)
Last update
Jul 23, 2025

Study contacts

Yun Zhang
Contact
bigzyun1977@zju.edu.cn
086-18058715288
Jian Zhang
Contact
johnzhang@zju.edu.cn
086-18758197996

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion